Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein

Journal of Biological Chemistry

Volumn 290, Issue 16, 2015, Pages 10504-10517

  Pery, Erez ^a   Sheehy, Ann ^b   Nebane, N Miranda ^c   Brazier, Andrew Jay ^a   Misra, Vikas ^a   Rajendran, Kottampatty S ^a   Buhrlage, Sara J ^a   Mankowski, Marie K ^c   Rasmussen, Lynn ^c   White, E Lucile ^c   Ptak, Roger G ^c   Gabuzda, Dana ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Interdisciplinary Studies   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; BLOOD; CELLS; CYTOLOGY; ENERGY TRANSFER; FLUORESCENCE; MOBILE SECURITY; T-CELLS; VIRUSES;

ANTIVIRAL ACTIVITIES; COMPOUND LIBRARIES; CYTIDINE DEAMINASE; MOLECULAR LIBRARIES; PERIPHERAL BLOOD MONONUCLEAR CELLS; STRUCTURE ACTIVITY RELATIONSHIPS; THERAPEUTIC TARGETS; TIME-RESOLVED FLUORESCENCE;

DISEASES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN; APOBEC3G PROTEIN, HUMAN; ATP DEPENDENT 26S PROTEASE; CYTIDINE DEAMINASE; MOLECULAR LIBRARY; PROTEASOME; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; VERO CELL LINE; VIRION; VIRUS INFECTIVITY; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; BIOASSAY; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; METABOLISM; MOLECULAR LIBRARY; MONONUCLEAR CELL; PHARMACOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; BIOLOGICAL ASSAY; CELL LINE; CYTIDINE DEAMINASE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; HEK293 CELLS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; PRIMARY CELL CULTURE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84927933739     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.626903     Document Type: Article

References (70)

1. Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., Hance, A. J., Heidmann, T., and Schwartz, O. (2005) APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433, 430-433
2. Esnault, C., Millet, J., Schwartz, O., and Heidmann, T. (2006) Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34, 1522-1531
3. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809
4. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103
5. Chaipan, C., Smith, J. L., Hu, W. S., and Pathak, V. K. (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 87, 444-453
6. Miyagi, E., Opi, S., Takeuchi, H., Khan, M., Goila-Gaur, R., Kao, S., and Strebel, K. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81, 13346-13353
7. Schumacher, A. J., Haché, G., Macduff, D. A., Brown, W. L., and Harris, R. S. (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82, 2652-2660
8. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98
9. Gillick, K., Pollpeter, D., Phalora, P., Kim, E. Y., Wolinsky, S. M., and Malim, M. H. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 87, 1508-1517
10. Bishop, K. N., Holmes, R. K., and Malim, M. H. (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80, 8450-8458
11. Guo, F., Cen, S., Niu, M., Yang, Y., Gorelick, R. J., and Kleiman, L. (2007) The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81, 11322-11331
12. Holmes, R. K., Malim, M. H., and Bishop, K. N. (2007) APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32, 118-128
13. Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J., and Yu, X. F. (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238-7248
14. Newman, E. N., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H., and Sheehy, A. M. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166-170
15. Shindo, K., Takaori-Kondo, A., Kobayashi, M., Abudu, A., Fukunaga, K., and Uchiyama, T. (2003) The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278, 44412-44416
16. Conticello, S. G., Harris, R. S., and Neuberger, M. S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013
17. Liu, B., Sarkis, P. T., Luo, K., Yu, Y., and Yu, X. F. (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79, 9579-9587
18. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403
19. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792-7798
20. Mehle, A., Thomas, E. R., Rajendran, K. S., and Gabuzda, D. (2006) A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281, 17259-17265
21. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407
22. Stopak, K., de Noronha, C., Yonemoto, W., and Greene, W. C. (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591-601
23. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060
24. Yu, Y., Xiao, Z., Ehrlich, E. S., Yu, X., and Yu, X. F. (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18, 2867-2872
25. Mehle, A., Goncalves, J., Santa-Marta, M., McPike, M., and Gabuzda, D. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866
26. Paul, I., Cui, J., and Maynard, E. L. (2006) Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 103, 18475-18480
27. Stanley, B. J., Ehrlich, E. S., Short, L., Yu, Y., Xiao, Z., Yu, X. F., and Xiong, Y. (2008) Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82, 8656-8663
28. Wang, X., Wang, X., Zhang, H., Lv, M., Zuo, T., Wu, H., Wang, J., Liu, D., Wang, C., Zhang, J., Li, X., Wu, J., Yu, B., Kong, W., and Yu, X. (2013) Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif. Retrovirology 10, 94
29. Jäger, S., Kim, D. Y., Hultquist, J. F., Shindo, K., LaRue, R. S., Kwon, E., Li, M., Anderson, B. D., Yen, L., Stanley, D., Mahon, C., Kane, J., Franks-Skiba, K., Cimermancic, P., Burlingame, A., Sali, A., Craik, C. S., Harris, R. S., Gross, J. D., and Krogan, N. J. (2012) Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature 481, 371-375
30. Zhang, W., Du, J., Evans, S. L., Yu, Y., and Yu, X. F. (2012) T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376-379
31. Kao, S., Khan, M. A., Miyagi, E., Plishka, R., Buckler-White, A., and Strebel, K. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77, 11398-11407
32. Kao, S., Miyagi, E., Khan, M. A., Takeuchi, H., Opi, S., Goila-Gaur, R., and Strebel, K. (2004) Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1, 27
33. Santa-Marta, M., da Silva, F. A., Fonseca, A. M., and Goncalves, J. (2005) HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280, 8765-8775
34. Bogerd, H. P., Doehle, B. P., Wiegand, H. L., and Cullen, B. R. (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 101, 3770-3774
35. Mangeat, B., Turelli, P., Liao, S., and Trono, D. (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279, 14481-14483
36. Mariani, R., Chen, D., Schröfelbauer, B., Navarro, F., König, R., Bollman, B., Münk, C., Nymark-McMahon, H., and Landau, N. R. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31
37. Schröfelbauer, B., Chen, D., and Landau, N. R. (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 101, 3927-3932
38. Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K., and Pathak, V. K. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U.S.A. 101, 5652-5657
39. Huthoff, H., and Malim, M. H. (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 81, 3807-3815
40. Mehle, A., Wilson, H., Zhang, C., Brazier, A. J., McPike, M., Pery, E., and Gabuzda, D. (2007) Identification of anAPOBEC3Gbinding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81, 13235-13241
41. Russell, R. A., and Pathak, V. K. (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201-8210
42. Schröfelbauer, B., Senger, T., Manning, G., and Landau, N. R. (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80, 5984-5991
43. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D., and Bieniasz, P. D. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1, e6
44. Tian, C., Yu, X., Zhang, W., Wang, T., Xu, R., and Yu, X. F. (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80, 3112-3115
45. Wichroski, M. J., Ichiyama, K., and Rana, T. M. (2005) Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280, 8387-8396
46. Pery, E., Rajendran, K. S., Brazier, A. J., and Gabuzda, D. (2009) Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83, 2374-2381
47. Yamashita, T., Kamada, K., Hatcho, K., Adachi, A., and Nomaguchi, M. (2008) Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 10, 1142-1149
48. Dang, Y., Wang, X., York, I. A., and Zheng, Y. H. (2010) Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84, 8561-8570
49. Dang, Y., Davis, R. W., York, I. A., and Zheng, Y. H. (2010) Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84, 5741-5750
50. Nathans, R., Cao, H., Sharova, N., Ali, A., Sharkey, M., Stranska, R., Stevenson, M., and Rana, T. M. (2008) Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26, 1187-1192
51. Xiao, Z., Ehrlich, E., Luo, K., Xiong, Y., and Yu, X. F. (2007) Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21, 217-222
52. Zuo, T., Liu, D., Lv, W., Wang, X., Wang, J., Lv, M., Huang, W., Wu, J., Zhang, H., Jin, H., Zhang, L., Kong, W., and Yu, X. (2012) Small-molecule inhibition of humanimmunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J. Virol. 86, 5497-5507
53. Knecht, W., and Löffler, M. (2000) Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism. FEBS Lett. 467, 27-30
54. Cen, S., Peng, Z. G., Li, X. Y., Li, Z. R., Ma, J., Wang, Y. M., Fan, B., You, X. F., Wang, Y. P., Liu, F., Shao, R. G., Zhao, L. X., Yu, L., and Jiang, J. D. (2010) Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285, 16546-16552
55. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905
56. Ptak, R. G., Gallay, P. A., Jochmans, D., Halestrap, A. P., Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., de Béthune, M. P., Neyts, J., De Clercq, E., Dumont, J. M., Scalfaro, P., Besseghir, K., Wenger, R. M., and Rosenwirth, B. (2008) Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 52, 1302-1317
57. Goncalves, J., Jallepalli, P., and Gabuzda, D. H. (1994) Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 68, 704-712
58. Brown, H. E., Chen, H., and Engelman, A. (1999) Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis. J. Virol. 73, 9011-9020
59. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650
60. Nguyen, K. L., llano, M., Akari, H., Miyagi, E., Poeschla, E. M., Strebel, K., and Bour, S. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319, 163-175
61. Zheng, Y. H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., and Peterlin, B. M. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073-6076
62. Gartner, S., Markovits, P., Markovitz, D. M., Kaplan, M. H., Gallo, R. C., and Popovic, M. (1986) The role of mononuclear phagocytes in HTLVIII/LAV infection. Science 233, 215-219
63. Louwagie, J., Delwart, E. L., Mullins, J. I., McCutchan, F. E., Eddy, G., and Burke, D. S. (1994) Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. AIDS Res. Hum. retroviruses 10, 561-567
64. Buckheit, R. W., Jr., and Swanstrom, R. (1991) Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retroviruses 7, 295-302
65. Goncalves, J., Korin, Y., Zack, J., and Gabuzda, D. (1996) Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 70, 8701-8709
66. Yu, Q., Chen, D., König, R., Mariani, R., Unutmaz, D., and Landau, N. R. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279, 53379-53386
67. Siu, K. K., Sultana, A., Azimi, F. C., and Lee, J. E. (2013) Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 4, 2593
68. Kitamura, S., Ode, H., Nakashima, M., Imahashi, M., Naganawa, Y., Kurosawa, T., Yokomaku, Y., Yamane, T., Watanabe, N., Suzuki, A., Sugiura, W., and Iwatani, Y. (2012) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19, 1005-1010
69. Aydin, H., Taylor, M. W., and Lee, J. E. (2014) Structure-guided analysis of the human APOBEC3-HIV restrictome. Structure 22, 668-684
70. Bohn, M. F., Shandilya, S. M., Albin, J. S., Kouno, T., Anderson, B. D., McDougle, R. M., Carpenter, M. A., Rathore, A., Evans, L., Davis, A. N., Zhang, J., Lu, Y., Somasundaran, M., Matsuo, H., Harris, R. S., and Schiffer, C. A. (2013) Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21, 1042-1050